Cargando…

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™

BACKGROUND: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus. Infections due to S. aureus with elevated vancomycin (VAN) minimum inhibitory concentrations (MIC) are associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobs, Micah, Nwaigwe, Casmiar, Clay, Candice, Barnes, Chris, Castaneda-Ruiz, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255514/ http://dx.doi.org/10.1093/ofid/ofy210.2022

Ejemplares similares

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Sternal osteomyelitis secondary to Aspergillus fumigatus after cardiothoracic surgery
por: Routray, Chittaranjan, et al.
Publicado: (2020)

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials
por: Nogid, Boris, et al.
Publicado: (2018)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method
por: Ross, James E., et al.
Publicado: (2014)

473 Comparison of MicroScan System Prompt and Turbidity Methods for Measuring Vancomycin Minimum inhibitory concentration (MIC) against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 2ug/ml, the Clinical Implications and economic impact of using alternative antimicrobial agents to vancomycin for MRSA with possible MIC of 2ug/ml
por: Kamran, Amir, et al.
Publicado: (2014)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital
por: Joana, Silvestre, et al.
Publicado: (2013)

Vancomycin MIC Distribution among Methicillin-Resistant Staphylococcus Aureus. Is Reduced Vancomycin Susceptibility Related To MIC Creep?
por: Othman, Hala B., et al.
Publicado: (2018)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Sustained Transmission of Neisseria gonorrhoeae Strains with High-Level Azithromycin Resistance (MIC ≥ 256 μg/mL) in Argentina, 2018 to 2022
por: Gianecini, Ricardo Ariel, et al.
Publicado: (2023)

EVALUATION OF METHODS IN DETECTING VANCOMYCIN MIC AMONG MRSA ISOLATES AND THE CHANGES IN ACCURACY RELATED TO DIFFERENT MIC VALUES
por: Rossatto, Fernanda Cristina Possamai, et al.
Publicado: (2014)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Clinical Implications of Species Identification in Monomicrobial Aeromonas Bacteremia
por: Wu, Chi-Jung, et al.
Publicado: (2015)

Wohlfahrtiimonas chitiniclastica Monomicrobial Bacteremia in a Homeless Man
por: Harfouch, Omar, et al.
Publicado: (2021)

High Vancomycin MIC and Complicated Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aguado, Jose Maria, et al.
Publicado: (2011)

Monomicrobial Necrotizing Fasciitis Caused by Aeromonas hydrophila and Klebsiella pneumoniae
por: Tsai, Yao-Hung, et al.
Publicado: (2015)

Predictors for gram-negative monomicrobial necrotizing fasciitis in southern Taiwan
por: Huang, Tsung-Yu, et al.
Publicado: (2020)

An Atypical Case of Monomicrobial Clostridioides difficile Septicemia With No Gastrointestinal Manifestations
por: Wang, Liqian, et al.
Publicado: (2022)

Different Antimicrobial Susceptibility Testing Methods to Determine Vancomycin Susceptibility and MIC for Staphylococcus aureus with Reduced Vancomycin Susceptibility
por: Chung, Hae-Sun, et al.
Publicado: (2022)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination
por: Huband, Michael D., et al.
Publicado: (2023)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs
por: Crompton, Jason A., et al.
Publicado: (2010)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

2371. Monomicrobial Gram-Negative Necrotizing Fasciitis: An Uncommon but Fatal Syndrome
por: Park, Se Yoon, et al.
Publicado: (2018)

Clinical Profile of Monomicrobial Corynebacterium Hip and Knee Periprosthetic Joint Infections
por: Tabaja, Hussam, et al.
Publicado: (2022)

Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric Staphylococcus aureus Pneumonia
por: McNeil, Jonathon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vb1opdg3it9oprp1o8vhqfbroj